Why the study?
The impact of neurodevelopmental disorder-associated variants on KCNQ3 channel function remains poorly understood, and existing treatments have significant side effects.
Polyunsaturated fatty acids can restore function to KCNQ3 channels with neurodevelopmental disorder-associated mutations, suggesting therapeutic potential for KCNQ3-based channelopathies.
This is the authors' abstract. We don't add key points for this paper.
A major driver of neuronal hyperexcitability is dysfunction of K⁺ channels, including voltage-gated KCNQ2/3 channels. Their hyperpolarized midpoint of activation and slow activation and deactivation kinetics produce a current that regulates membrane potential and impedes repetitive firing. Inherited mutations in KCNQ2 and KCNQ3 are linked to a wide spectrum of neurodevelopmental disorders (NDDs), ranging from benign familial neonatal seizures to severe epileptic encephalopathies and autism spectrum disorders. However, the impact of these variants on the molecular mechanisms underlying KCNQ3 channel function remains poorly understood and existing treatments have significant side effects. Here, we use voltage clamp fluorometry, molecular dynamic simulations, and electrophysiology to investigate NDD-associated variants in KCNQ3 channels. We identified two distinctive mechanisms by which loss- and gain-of function NDD-associated mutations in KCNQ3 affect channel gating: one directly affects S4 movement while the other changes S4-to-pore coupling. MD simulations and electrophysiology revealed that polyunsaturated fatty acids (PUFAs) primarily target the voltage-sensing domain in its activated conformation and form a weaker interaction with the channel's pore. Consistently, two such compounds yielded partial and complete functional restoration in R227Q- and R236C-containing channels, respectively. Our results reveal the potential of PUFAs to be developed into therapies for diverse KCNQ3-based channelopathies.
Answers are grounded in this paper and cite their sources.
PUFAs may offer a therapeutic avenue for KCNQ3 channelopathies; hypothesis-generating in animal models and requires human validation.
No takes yet. Share an insight, caveat, or question.
Edmond et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: